[go: up one dir, main page]

WO2014027334A3 - Oral pharmaceutical composition in the form of microspheres and preparation method - Google Patents

Oral pharmaceutical composition in the form of microspheres and preparation method Download PDF

Info

Publication number
WO2014027334A3
WO2014027334A3 PCT/IB2013/056690 IB2013056690W WO2014027334A3 WO 2014027334 A3 WO2014027334 A3 WO 2014027334A3 IB 2013056690 W IB2013056690 W IB 2013056690W WO 2014027334 A3 WO2014027334 A3 WO 2014027334A3
Authority
WO
WIPO (PCT)
Prior art keywords
microspheres
preparation
pharmaceutical composition
oral pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/056690
Other languages
Spanish (es)
French (fr)
Other versions
WO2014027334A2 (en
Inventor
Gustavo BARRANCO HERNÁNDEZ
María del Coral LUNA GUIZA
Héctor SENOSIAIN ARROYO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Senosiain SA de CV
Original Assignee
Laboratorios Senosiain SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014027334(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Senosiain SA de CV filed Critical Laboratorios Senosiain SA de CV
Publication of WO2014027334A2 publication Critical patent/WO2014027334A2/en
Publication of WO2014027334A3 publication Critical patent/WO2014027334A3/en
Priority to CR20150077A priority Critical patent/CR20150077A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition in the form of microparticles primarily made up of: a) an inert core; b) a layer of active principle formed by spraying onto the inert core, and c) optionally, a second coating comprising one or more layers of pharmaceutically acceptable excipient(s) and/or drug(s). Said composition may be used to treat conditions resulting from excessive retention of water and/or electrolytes, cardiovascular disease, renovascular disease, diabetes, endothelial dysfunction, cirrhosis, preeclampsia, nephropathy, peripheral vascular disease and hypertension, among others.
PCT/IB2013/056690 2012-08-17 2013-08-16 Oral pharmaceutical composition in the form of microspheres and preparation method Ceased WO2014027334A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CR20150077A CR20150077A (en) 2012-08-17 2015-02-13 ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2012009583A MX351059B (en) 2012-08-17 2012-08-17 Oral pharmaceutical composition in the form of microspheres and preparation method.
MXMX/A/2012/009583 2012-08-17

Publications (2)

Publication Number Publication Date
WO2014027334A2 WO2014027334A2 (en) 2014-02-20
WO2014027334A3 true WO2014027334A3 (en) 2014-04-10

Family

ID=50435594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/056690 Ceased WO2014027334A2 (en) 2012-08-17 2013-08-16 Oral pharmaceutical composition in the form of microspheres and preparation method

Country Status (8)

Country Link
CL (1) CL2015000375A1 (en)
CO (1) CO7310526A2 (en)
CR (1) CR20150077A (en)
DO (1) DOP2015000028A (en)
GT (1) GT201500035A (en)
MX (1) MX351059B (en)
PE (1) PE20150710A1 (en)
WO (1) WO2014027334A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106821996A (en) * 2017-03-01 2017-06-13 华益药业科技(安徽)有限公司 Enalapril maleate granule and preparation method thereof
CN108472257B (en) * 2015-12-28 2020-12-04 新丰制药株式会社 drug combination preparation

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014154606A1 (en) 2013-03-27 2014-10-02 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
CN104523710B (en) * 2014-12-30 2018-05-25 石药集团欧意药业有限公司 A kind of bisulfate clopidogrel aspirin Composite Double synusia and preparation method thereof
EP3582777A4 (en) 2017-02-17 2020-12-23 Unichem Laboratories Ltd Pharmaceutical composition of apixaban
DK3781132T3 (en) 2018-04-16 2024-04-22 Bristol Myers Squibb Co APIXABAN FORMULATIONS
KR102045721B1 (en) * 2019-03-27 2019-11-18 주식회사 씨트리 Compositions of dispersion phase for preparation of apixaban loaded microsphere and biocompatible polymer based apixaban loaded microsphere prepared therefrom
EP4106731A4 (en) * 2020-02-19 2024-04-24 Nano Pharmasolutions, Inc. THERAPEUTIC NANOPARTICLES AND MANUFACTURING METHODS
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
CN113413364A (en) * 2021-05-31 2021-09-21 辰欣药业股份有限公司 Enoxaparin sodium injection and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039052A2 (en) * 2006-09-25 2008-04-03 ESPINOSA ABDALA, Leopoldo de Jesús Process for stabilizing famotidine
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2009007808A1 (en) * 2007-07-11 2009-01-15 Laboratorios Senosiain S.A. De C.V. Combined pharmaceutical composition
US20100092453A1 (en) * 2006-01-27 2010-04-15 Anne Marie Healy Method of producing porous microparticles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092453A1 (en) * 2006-01-27 2010-04-15 Anne Marie Healy Method of producing porous microparticles
WO2008039052A2 (en) * 2006-09-25 2008-04-03 ESPINOSA ABDALA, Leopoldo de Jesús Process for stabilizing famotidine
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2009007808A1 (en) * 2007-07-11 2009-01-15 Laboratorios Senosiain S.A. De C.V. Combined pharmaceutical composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472257B (en) * 2015-12-28 2020-12-04 新丰制药株式会社 drug combination preparation
CN106821996A (en) * 2017-03-01 2017-06-13 华益药业科技(安徽)有限公司 Enalapril maleate granule and preparation method thereof

Also Published As

Publication number Publication date
CL2015000375A1 (en) 2015-07-10
WO2014027334A2 (en) 2014-02-20
MX351059B (en) 2017-09-29
PE20150710A1 (en) 2015-05-28
MX2012009583A (en) 2014-02-26
GT201500035A (en) 2017-10-24
CR20150077A (en) 2015-05-13
DOP2015000028A (en) 2015-03-15
CO7310526A2 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
WO2014027334A3 (en) Oral pharmaceutical composition in the form of microspheres and preparation method
WO2011039768A3 (en) Pharmaceutical compositions for reducing alcohol-induced dose dumping
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
WO2012031124A3 (en) Drug formulations using water soluble antioxidants
WO2009063222A3 (en) Solid compositions
WO2011123836A3 (en) Pharmaceutical formulations for the treatment of overactive bladder
WO2012131463A3 (en) Controlled release pharmaceutical dosage forms
BRPI0910758A2 (en) thermostable solid composition, pharmaceutical composition, processes for preparing a thermostable solid composition and a pharmaceutical composition, method for improving the bioavailability of a pharmaceutically active ingredient, and
LT2808325T (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
WO2011140446A3 (en) Pharmaceutical formulations
WO2012064150A3 (en) Composition comprising benproperine derivatives as active ingredients for preventing and treating angiogenesis-related diseases
WO2015003479A3 (en) Orally administered solid pellet for infants and children and preparation method therefor
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2015038552A3 (en) Aspirin formulation for increased efficacy
WO2012145575A3 (en) Therapy for leukemia
MD4563B1 (en) Co-micronisation product comprising ulipristal acetate
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
HK1223825A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
EA201590474A1 (en) PHARMACEUTICAL COMPOSITION BASED ON COMPOSITE CAPSULES INCLUDING IRBESARTAN AND HMG-COA REDUCTASE INHIBITOR
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
WO2014141295A3 (en) Treatment and prophylaxis of kidney diseases
WO2012077968A3 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2012164575A3 (en) Amorphous ritonavir co-precipitated
WO2014085494A8 (en) Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
WO2011139414A3 (en) Dexlansoprazole polymorphic forms

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: CR2015-000077

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 000210-2015

Country of ref document: PE

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2015000375

Country of ref document: CL

WWE Wipo information: entry into national phase

Ref document number: 15048826

Country of ref document: CO

122 Ep: pct application non-entry in european phase

Ref document number: 13872270

Country of ref document: EP

Kind code of ref document: A2